Barclays
QNCX icon

Barclays’s Quince Therapeutics QNCX Stock Holding History

Barclays’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 5357
2025
Q4 		– Hold
0
– – – 5152
2025
Q3 		– Hold
0
– – – 5400
2025
Q2 		– Hold
0
– – – 5127
2025
Q1 		– Sell
-1
Closed -$305 – 5157
2024
Q4 		$187 Hold
1
– – ﹤0.01% 5175
2024
Q3 		$78 Hold
1
– – ﹤0.01% 5191
2024
Q2 		$75 Hold
1
– – ﹤0.01% 4762
2024
Q1 		$106 Hold
1
– – ﹤0.01% 5000
2023
Q4 		$105 Hold
1
– – ﹤0.01% 5168
2023
Q3 		$224 Hold
1
– – ﹤0.01% 4532
2023
Q2 		$151 Hold
1
– – ﹤0.01% 4427
2023
Q1 		$156 Buy
+1
New +$196 ﹤0.01% 4987
2022
Q3 		– Sell
-5
Closed -$2K – 5064
2022
Q2 		$2K Sell
5
-17
-77% -$12K ﹤0.01% 4888
2022
Q1 		$26K Sell
22
-108
-83% -$147K ﹤0.01% 4355
2021
Q4 		$329K Buy
130
+89
+217% +$543K ﹤0.01% 3379
2021
Q3 		$756K Buy
41
+27
+193% +$429K ﹤0.01% 2952
2021
Q2 		$143K Sell
14
-53
-79% -$444K ﹤0.01% 3698
2021
Q1 		$480K Buy
67
+40
+148% +$288K ﹤0.01% 3200
2020
Q4 		$149K Sell
27
-9
-25% -$79.7K ﹤0.01% 3940
2020
Q3 		$360K Sell
36
-7
-16% -$63.7K ﹤0.01% 3466
2020
Q2 		$400K Buy
43
+24
+126% +$220K ﹤0.01% 3526
2020
Q1 		$175K Sell
19
-42
-69% -$415K ﹤0.01% 4407
2019
Q4 		$680K Buy
61
+53
+663% +$320K ﹤0.01% 4024
2019
Q3 		$39K Sell
8
-22
-73% -$135K ﹤0.01% 6009
2019
Q2 		$253K Buy
+30
New +$179K ﹤0.01% 4900

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays's QNCX Position: Q1 2026 in Review

Barclays held its Quince Therapeutics (QNCX) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5357.

Barclays first reported a position in QNCX in Q2 2019 and has held it in 21 quarters since. The position peaked at $756K in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Barclays held 0 shares of Quince Therapeutics worth $0 as of Q1 2026.
  • Barclays left its Quince Therapeutics share count unchanged in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5357 holding.
  • Barclays first reported a position in Quince Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Barclays's Quince Therapeutics position peaked at $756K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.